This year’s hot topics include novel approaches in the fields of oncology and CNS disorders. In addition, exciting projects in the fields of infection research, haematology and gene and cell therapy will be presented. Ascenion’s partners contribute a total of eight projects:
- Novel Darobactin derivatives - Highly active antibacterials against Gram-negative bacteria
(Helmholtz-Zentrum für Infektionsforschung) - BreakTag - Novel method for detection of DS-breaks and analysis of CRISPR-induced on- and off-target effects
(Institut für Molekulare Biologie) - Ex-vivo method for the determination of oxidative stress and diagnosis of ferroptosis-associated diseases
(Helmholtz Munich) - Method and kit for early detection of preeclampsia
(Max Delbrück Center) - Otviciclib - a new pan-CDK inhibitor in oncology
(Medizinische Universität Innsbruck) - Automated production of cardiac organoids
(Medizinische Hochschule Hannover) - INSPECT - Intron encoded reporter transcripts for minimally invasive monitoring of coding and non-coding RNAs
(Helmholtz Munich) - Transforming single-cell technologies into clinical and commercial applications
(Charité – Universitätsklinikum Berlin)
A further program highlight is BioVaria’s dedicated Startup Pitch & Partner program. The expanded format of the Startup Pitch & Partner program provides attractive opportunities for entrepreneurs and venture capitalists, with interactive pitches and speed dating between startups and investors. In addition, and for the first time, young scientists will present their innovative projects in the new "Early Stage Innovations" session where teams from Ascenion's Life Science Digital Hub, which is supported by GO-Bio initial, and ForTra-funded projects will participate.
Don’t miss your chance, join in!
- Register here (early bird ends on 15 March)
- Browse this year’s technologies
This year’s selected start-ups will be unveiled soon. Stay tuned!